Table 5.

Model Generated from Clinically Defined Predictors

Effect	Estimate	Standardized Est
Intercept	4.639526	0
Baseline Visit Count	0.001981	0.02366
Baseline RDCI Score	0.005026	0.00521
Baseline Labtest Days for Chem Panel	-0.001423	-0.0026
Baseline Primary Care Visit Count	0.005222	0.01475
Baseline Occupational Visit Count	0.010707	0.01553
Bupropion Rx in Baseline (Y/N)	0.106174	0.0135
Distinct VA Drug Class Rx	0.030526	0.13957
Joint Injection Count	0.019454	0.0097
Rheumatism, Unspecified And Fibrosis Dx Count (ICD:729)	0.008102	0.00519
Baseline Surgery Count	-0.058006	-0.0162
Days End of Prednisone	-0.000912	-0.09845
Days End of Sulfasalazine	-0.000063599	-0.00505
Baseline PDC for Etanercept	-0.152669	-0.02073
Days Start of Golimumab	-0.001374	-0.00927
Baseline PDC for Non-Biologic DMARDs	-0.708075	-0.16342
Start Methotrexate in 14 Days after Index Date (Y/N)	0.077462	0.01148
Start Leflunomide in 14 Days after Index Date (Y/N)	0.073709	0.00598
Start in TNFi Biologic DMARDs in 14 Days after Index Date (Count of distinct Rx)	0.542521	0.06171
Start in Non-Biologic DMARDs in 14 Days after Index Date (Count of distinct Rx)	0.380811	0.09612
Start in Steroid in 14 Days after Index Date (Count of distinct Rx)	0.45952	0.06632
Rheumatism, Unspecified And Fibrosis Dx (ICD:729) (Y/N)	0.003294	0.00075
Baseline Labtest for Chem Panel (Y/N)	-0.482788	-0.0294
Baseline Labtest for RF (Y/N)	0.022162	0.00714
Baseline Foot Surgery (Y/N)	0.037806	0.01158
Baseline Hand Surgery (Y/N)	0.105081	0.02942
Baseline Occupational Visit (Y/N)	0.116702	0.02344
Baseline Rheumatology Visit (Y/N)	-0.033104	-0.00143
Start in Non-Biologic DMARDs in 14 Days after Index Date (Y/N)	0.340854	0.07459
Start in DMARDs in 14 Days after Index Date (Y/N)	0.590044	0.08356
Baseline Use of Sulfasalazine (Y/N)	0.158241	0.03893
Baseline Use of Rituximab (Y/N)	0.112073	0.00872
Baseline Use of Infliximab (Y/N)	0.003816	0.00057